Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Shares Outstanding (Diluted Average): 2020-2025

Historic Shares Outstanding (Diluted Average) for Crinetics Pharmaceuticals (CRNX) over the last 5 years, with Sep 2025 value amounting to $94.2 million.

  • Crinetics Pharmaceuticals' Shares Outstanding (Diluted Average) rose 17.63% to $94.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.2 million, marking a year-over-year increase of 17.63%. This contributed to the annual value of $80.8 million for FY2024, which is 39.11% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Shares Outstanding (Diluted Average) of $94.2 million as of Q3 2025, which was up 0.45% from $93.8 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' Shares Outstanding (Diluted Average)'s 5-year high stood at $94.2 million during Q3 2025, with a 5-year trough of $37.1 million in Q2 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $79.0 million (2024), whereas its average is $74.2 million.
  • Data for Crinetics Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY spiked of 45.57% (in 2024) over the last 5 years.
  • Crinetics Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarterly) stood at $38.4 million in 2021, then skyrocketed by 35.24% to $52.0 million in 2022, then increased by 11.71% to $58.1 million in 2023, then surged by 39.11% to $80.8 million in 2024, then grew by 17.63% to $94.2 million in 2025.
  • Its last three reported values are $94.2 million in Q3 2025, $93.8 million for Q2 2025, and $93.1 million during Q1 2025.